Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas Licenses Fidaxomicin from Optimer
February 21, 2011
- Sawai: First 3-Qtr Sales, Profits Show Double-Digit Growth
February 21, 2011
- Astellas Creates Sales Subsidiary in Australia
February 21, 2011
- PHARMA JAPAN Lexicon: 47
February 21, 2011
- Santen Allies with DBJ
February 21, 2011
- Korosho to Review Current Risk Classification of OTC Drugs
February 21, 2011
- Otsuka Holds Sufficient Stock of IFN from Hayashibara
February 21, 2011
- AZ Stops Multinational PIII Trial of Zibotentan
February 21, 2011
- Astellas Withdraws Application for Darexaban in Japan
February 21, 2011
- Toho Starts New OTC Drugs Sales System Jointly with eHealthcare
February 21, 2011
- Gov't-Industry Dialogue to Resume in March
February 21, 2011
- Introduce “Compendium System”to Solve Problems of Off-label Use: Dr Fujiwara of NCC Hospital
February 21, 2011
- RDKK to Launch Gene Diagnostic Agent for K-RAS Mutation in 2013
February 14, 2011
- Pfizer's Crizotinib Designated as Orphan Drug
February 14, 2011
- TOS Disappointed about Delay in Approval of Contrave
February 14, 2011
- Kyowa Kirin to Create Its Own Marketing Network in US
February 14, 2011
- Pegasys, Copegus Granted Priority Review for CHC-Related Compensated Liver Cirrhosis
February 14, 2011
- Eisai Committed to Developing Eritoran: President Naito
February 14, 2011
- FDA Requires Additional CV Safety Study for Approval of Contrave
February 14, 2011
- Pfizer Japan, Takeda to Copromote Tofacitinib in Japan
February 14, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…